News
Yourlocation: Home > News > The potential of N-methyl pyrrolidone to prevent osteoporosis and enhance bone regeneration in vivo (1139.5)
The potential of N-methyl pyrrolidone to prevent osteoporosis and enhance bone regeneration in vivo (1139.5).Osteoporosis is a chronic, skeletal disease highly prevalent in post-menopausal women influenced by hormonal factors causing a huge burden on health care in an aging society. We previously demonstrated that N-methyl pyrrolidone  NMP is a bioactive drug which enhances bone regeneration and acts as an enhancer of bone morphogenetic protein (BMP) NMP also inhibits osteoclast differentiation and attenuates bone resorption. The present study used animal models established for the evaluation of enhanced osteoporosis through double ovariectomy (OVX) and treated systemically with different doses of N-methyl pyrrolidone (NMP). With this treatment we want to describe the preventive effect of N-methyl pyrrolidone NMP on bone mass loss. Female Sprague-Dawley rats with an approximate weight of 220-250g were randomly divided into sham-operated group (Sham) either treated or not with NMP and four ovariectomized subgroups as OVX (control), OVX treated with three different graded doses of N-methyl pyrrolidone NMP. Bilateral ovariectomy or Sham operations were performed as previously designated and the weight of the animals was measured weekly. We assessed the pharmacological effects of N-methyl pyrrolidone NMP against osteoporosis by evaluating the body weight, serum biochemical parameters, bone mineral density (BMD), dynamic histomorphometry of bone and bone histomorphology. The results showed that over a 15 week period, in OVX rats the increase in body weight, serum osteocalcin levels and decreases of BMD were significantly reversed by N-methyl pyrrolidone NMP treatment. Additionally, the effect of the three different treatment dosages of N-methyl pyrrolidone NMP correlated dose-dependently with their effect on bone resorption. Mineral apposition rate (MAR) showed the protective activity of NMP through promotion of bone formation and suppression of bone resorption. These results suggest that N-methyl pyrrolidone NMP has a remarkable antiosteoporotic activity, and may be a promising candidate for treatment of postmenopausal osteoporosis induced by estrogen deficiency.

Address:河南省濮阳市胜利西路 Tel:0393-4411771 Fax:- Email:myj@myj2002.com
Copyright ©

Reduce
Open